Receive our newsletter – data, insights and analysis delivered to you
  1. News
  2. Company News
August 13, 2018updated 22 Nov 2021 7:50am

Samsung Bioepis to begin Phase l trial of SB26 for pancreatitis

Samsung Bioepis is set to start a Phase l trial to investigate SB26, also known as TAK-671, for the treatment of severe acute pancreatitis.

Samsung Bioepis is set to start a Phase l trial to investigate SB26, also known as TAK-671, for the treatment of severe acute pancreatitis.

Pancreatitis is caused by the inflammation of the pancreas, a large organ behind the stomach that produces digestive enzymes and various hormones.

Samsung’s planned Phase l trial is a randomised, double-blind, placebo-controlled, single and multiple-dose escalation study that intends to evaluate the safety, tolerability and pharmacokinetics of intravenous SB26 in healthy subjects.

Results from the trial are expected to be available by the third quarter of 2020.

Samsung Bioepis senior vice-president and Clinical Sciences Division head Chul Kim said: “The upcoming clinical trial marks a major milestone for those of us at Samsung Bioepis, as SB26 is set to become the first novel biologic candidate from our company to enter clinical trials.

“Acute pancreatitis remains one of the most common gastrointestinal conditions, affecting more patients every year.”

“Acute pancreatitis remains one of the most common gastrointestinal conditions, affecting more patients every year.

Content from our partners
Africa’s last mile: Building viable vaccine supply chains
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Patient-centric pharma logistics: How CRYOPDP delivers hope worldwide

“While mild acute pancreatitis is more easily treatable, severe acute pancreatitis, which affects approximately 20% of patients suffering from acute pancreatitis, can often be fatal. Unfortunately, treatment options remain extremely limited.”

SB26 is an ulinastatin-Fc (UTI-Fc) fusion protein developed to treat severe acute pancreatitis.

It has been developed under a risk-sharing strategic collaboration agreement between Samsung Bioepis and Takeda Pharmaceutical Company to jointly develop new biologic therapies.

SB26 combines Samsung Bioepis’ biologics development platform with Takeda’s expertise in drug development.

Related Companies

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU